Welcome to the forefront of conversational AI as we explore the fascinating world of AI chatbots in our dedicated blog series. Discover the latest advancements, applications, and strategies that propel the evolution of chatbot technology. From enhancing customer interactions to streamlining business processes, these articles delve into the innovative ways artificial intelligence is shaping the landscape of automated conversational agents. Whether you’re a business owner, developer, or simply intrigued by the future of interactive technology, join us on this journey to unravel the transformative power and endless possibilities of AI chatbots.
Parents were more willing to allow their children to receive a vaccine against human papillomavirus (HPV) if they interacted with a chatbot powered by artificial intelligence (AI) compared with parents who received no information about the vaccine.
The chatbot’s effects faded after 45 days, suggesting the benefits were short-lived, according to a randomized controlled trial of 1,297 parents of children not yet immunized against HPV. The results were published last week in JAMA Network Open.
The chatbot also performed no better than traditional public health materials, according to the clinical trial, which was led by researchers with the University of Pennsylvania’s computer and information science department. Public health materials, however, maintained a modest effect at 45 days.
The study measured self-reported likelihood of vaccinating a child against HPV within 12 months on a 100-point scale, with 0 indicating parents were extremely unlikely and 100 being extremely likely.
The trial was conducted online among adults in the United States, Canada, and the United Kingdom from March 3 to May 25, 2026. Researchers followed up with participants after 15 days and 45 days. All participants had at least one child eligible for HPV vaccination, which the American Academy of Pediatrics recommends for boys and girls aged 9 to 12.
“Well-designed public health messaging may match or exceed the impact of short chatbot conversations for HPV vaccine promotion,” the study authors concluded.
Today the head of Africa’s Centres for Disease Control and Prevention warned that thousands of case contacts have not been traced in the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC).
“If we don’t stop the outbreak very soon, it will be worse than what we had in West Africa and eastern DRC,” Africa CDC Director-General Jean Kaseya, MD, MPH, said during a virtual meeting of African heads of state in Burundi. Kaseya was referring to an outbreak in Guinea, Liberia, and Sierra Leone in 2014 to 2016 that killed more than 11,000 people.
The outbreak currently has at least 827 cases and 194 deaths, but it is largely uncontrolled in North and South Kivu and Ituri provinces. The outbreak is caused by the Bundibugyo strain of the virus, which has no vaccine or treatments.
Children diagnosed as having multisystem inflammatory syndrome in children (MIS-C) following COVID-19 infection are more likely to have new and lingering health conditions than those not diagnosed with MIS-C, according to study published last week in Pediatrics.
MIS-C, a rare but potentially deadly post-viral hyperinflammatory condition that often requires hospitalization, occurs in some children following COVID-19. While previous research indicated that some symptoms waned two years after infection, this new paper is the first to show that health complications can persist up to 4.5 years after COVID-19.
In the large retrospective cohort study, researchers from Albert Einstein College of Medicine examined the Montefiore Health System electronic health records of 173 children with MIS-C and 14,190 children without the condition. They compared the two groups’ health for up to 4.5 years after their COVID-19 diagnosis.
The broad multisystem risks underscore the need for structured follow-up of patients with MIS-C.
Having MIS-C contributed to children acquiring new chronic health conditions. These children experienced a nearly 14-fold higher chance of developing cardiovascular disease, including heart failure. Children who had MIS-C also were at an increased risk of high blood pressure; neurologic and psychological disorders such as stroke, depression, and anxiety; respiratory and gastrointestinal conditions; and chronic kidney disease and shock.
“The broad multisystem risks underscore the need for structured follow-up of patients with MIS-C,” the authors wrote. “Routine blood pressure monitoring is essential, given the markedly elevated risk of hypertension.”
In addition, the researchers recommend multidisciplinary follow-up for children who had MIS-C that incorporates screening for cardiovascular health, renal function, and neurologic and mental conditions.
“Long-term outcome patterns in our cohort showed a clear and persistent accumulation of multisystem morbidity among survivors of MIS-C compared to matched controls without MIS-C, with disparities widening steadily over 4.5 years,” the authors wrote.
The human papillomavirus (HPV) now causes more head and neck cancers than cervical cancers (part 2 of 3).
Erica Stum was a mother, a teacher, and a cervical cancer advocate. An HPV vaccine could have saved her life (part 1 of 3).
UN officials warn that increasing household transmission will affect children.
In a new Lancet study, researchers estimate the outbreak could be more than double current numbers.
For well over a year, public health experts have been planning how to protect fans from infectious diseases such as flu, COVID, and measles (part 1 of 2).
The guidance illustrates the growing chasm between the medical organization and the federal health agency.
Infections have been identified in New York, Maryland, and Virginia, with a death in Maryland.
Infections in US animals rise to 6 amid increasing concerns of further spread.
At least 515 cases have come from the DR Congo’s Ituri province.
Buckingham County, Virginia, has seen 88 cases in the past month.
Help make CIDRAP’s vital work possible
CIDRAP – Center for Infectious Disease Research & Policy
Research and Innovation Office, University of Minnesota, Minneapolis, MN
Email us
© 2026 Regents of the University of Minnesota. All rights Reserved.
The University of Minnesota is an equal opportunity educator and employer
Research and Innovation Office | Contact U of M | Privacy Policy
Newsletter subscribe
